The HSP90 inhibitor ganetespib potentiates the antitumor activity of EGFR tyrosine kinase inhibition in mutant and wild-type non-small cell lung cancer

Small molecule inhibitors of epidermal growth factor receptor (EGFR) tyrosine kinase activity, such as erlotinib and gefitinib, revolutionized therapy for non-small cell lung cancer (NSCLC) patients whose tumors harbor activating EGFR mutations. However, mechanisms to overcome the invariable develop...

Descripción completa

Detalles Bibliográficos
Autores principales: Smith, Donald L., Acquaviva, Jaime, Sequeira, Manuel, Jimenez, John-Paul, Zhang, Chaohua, Sang, Jim, Bates, Richard C., Proia, David A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer International Publishing 2014
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4457934/
https://www.ncbi.nlm.nih.gov/pubmed/25077897
http://dx.doi.org/10.1007/s11523-014-0329-6

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4457934/
https://www.ncbi.nlm.nih.gov/pubmed/25077897
http://dx.doi.org/10.1007/s11523-014-0329-6

Ejemplares similares